Dawn L Hershman1, Jennifer Tsui2, Jason D Wright2, Ellie J Coromilas2, Wei Yann Tsai2, Alfred I Neugut2. 1. Dawn L. Hershman, Jason D. Wright, Ellie J. Coromilas, and Alfred I. Neugut, Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons; and Dawn L. Hershman, Jennifer Tsui, Jason D. Wright, Wei Yann Tsai, and Alfred I. Neugut, Mailman School of Public Health, Columbia University, New York, NY. Dlh23@columbia.edu. 2. Dawn L. Hershman, Jason D. Wright, Ellie J. Coromilas, and Alfred I. Neugut, Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons; and Dawn L. Hershman, Jennifer Tsui, Jason D. Wright, Wei Yann Tsai, and Alfred I. Neugut, Mailman School of Public Health, Columbia University, New York, NY.
Abstract
PURPOSE: Nonadherence to adjuvant hormonal therapy is common and is associated with increased prescription copayment amount and black race. Studies suggest that household wealth may partly explain racial disparities. We investigated the impact of net worth on disparities in adherence and discontinuation. PATIENTS AND METHODS: We used the OptumInsight insurance claims database to identify women older than age 50 years diagnosed with early breast cancer, from January 1, 2007, to December 31, 2011, who were using hormonal therapy. Nonadherence was defined as a medication possession ratio of ≤ 80% of eligible days over a 2-year period. We evaluated the association of demographic and clinical characteristics, annual household income, household net worth (< $250,000, $250,000 to $750,000, or > $750,000), insurance type, and copayments (< $10, $10 to $20, or > $20) with adherence to hormonal therapy. Logistic regression analyses were conducted by sequentially adding sociodemographic and financial variables to race. RESULTS: We identified 10,302 patients; 2,473 (24%) were nonadherent. In the unadjusted analyses, adherence was negatively associated with black race (odds ratio [OR], 0.76; P < .001), advanced age, comorbidity, and Medicare insurance. Adherence was positively associated with medium (OR, 1.33; P < .001) and high (OR, 1.66; P < .001) compared with low net worth. The negative association of black race with adherence (OR, 0.76) was reduced by adding net worth to the model (OR, 0.84; P < .05). Correcting for other variables had a minimal impact on the association between race and adherence (OR, 0.87; P = .08). The interaction between net worth and race was significant (P < .01). CONCLUSION: We found that net worth partially explains racial disparities in hormonal therapy adherence. These results suggest that economic factors may contribute to disparities in the quality of care.
PURPOSE: Nonadherence to adjuvant hormonal therapy is common and is associated with increased prescription copayment amount and black race. Studies suggest that household wealth may partly explain racial disparities. We investigated the impact of net worth on disparities in adherence and discontinuation. PATIENTS AND METHODS: We used the OptumInsight insurance claims database to identify women older than age 50 years diagnosed with early breast cancer, from January 1, 2007, to December 31, 2011, who were using hormonal therapy. Nonadherence was defined as a medication possession ratio of ≤ 80% of eligible days over a 2-year period. We evaluated the association of demographic and clinical characteristics, annual household income, household net worth (< $250,000, $250,000 to $750,000, or > $750,000), insurance type, and copayments (< $10, $10 to $20, or > $20) with adherence to hormonal therapy. Logistic regression analyses were conducted by sequentially adding sociodemographic and financial variables to race. RESULTS: We identified 10,302 patients; 2,473 (24%) were nonadherent. In the unadjusted analyses, adherence was negatively associated with black race (odds ratio [OR], 0.76; P < .001), advanced age, comorbidity, and Medicare insurance. Adherence was positively associated with medium (OR, 1.33; P < .001) and high (OR, 1.66; P < .001) compared with low net worth. The negative association of black race with adherence (OR, 0.76) was reduced by adding net worth to the model (OR, 0.84; P < .05). Correcting for other variables had a minimal impact on the association between race and adherence (OR, 0.87; P = .08). The interaction between net worth and race was significant (P < .01). CONCLUSION: We found that net worth partially explains racial disparities in hormonal therapy adherence. These results suggest that economic factors may contribute to disparities in the quality of care.
Authors: Ann H Partridge; Laura Archer; Alice B Kornblith; Julie Gralow; Debjani Grenier; Edith Perez; Antonio C Wolff; Xiaofei Wang; Helen Kastrissios; Donald Berry; Clifford Hudis; Eric Winer; Hyman Muss Journal: J Clin Oncol Date: 2010-04-05 Impact factor: 44.544
Authors: Aliza K Fink; Jerry Gurwitz; William Rakowski; Edward Guadagnoli; Rebecca A Silliman Journal: J Clin Oncol Date: 2004-08-15 Impact factor: 44.544
Authors: Lindsey R Sangaralingham; Nilay D Shah; Xiaoxi Yao; Véronique L Roger; Shannon M Dunlay Journal: Circ Cardiovasc Qual Outcomes Date: 2016-05-10
Authors: Zhiyuan Zheng; Xuesong Han; Gery P Guy; Amy J Davidoff; Chunyu Li; Matthew P Banegas; Donatus U Ekwueme; K Robin Yabroff; Ahmedin Jemal Journal: Cancer Date: 2017-02-20 Impact factor: 6.860
Authors: Spyridoula Maraka; Raphael Mwangi; Xiaoxi Yao; Lindsey R Sangaralingham; Naykky M Singh Ospina; Derek T O'Keeffe; Rene Rodriguez-Gutierrez; Marius N Stan; Juan P Brito; Victor M Montori; Rozalina G McCoy Journal: J Clin Endocrinol Metab Date: 2019-04-24 Impact factor: 5.958
Authors: Mariana Chavez-MacGregor; Christina A Clarke; Daphne Y Lichtensztajn; Sharon H Giordano Journal: JAMA Oncol Date: 2016-03 Impact factor: 31.777